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The possibility of 5-aminolaevulinic acid-based photodynamic therapy (ALA-PDT) for liver cancer was investigated using a chemically
induced hepatocellular carcinoma (HCC) model. Endogenously synthesised protoporphyrin IX (PpIX) following the administration of
ALA is an effective photosensitiser for PDT. We determined the fluorescence intensity of PpIX in HCC and nontumoral tissue in the
liver. 5-Aminolaevulinic acid was intravenously injected to male Fisher rats with HCC at a dose of 500mgkg
 1, and the fluorescence
intensity in each tissue sample excised from liver was measured with a spectrofluorometer at 1, 3 and 6h after administration.
Fluorescence intensity was at a peak of 3h after administration in both HCC and nontumoral tissue. The accumulation of PpIX in
HCC was higher than that in the nontumoral tissue at 1h (Po0.001) and 3h (Po0.05) after ALA administration. Based on these
results, PDT was performed on HCC at 3h after 500mgkg
 1 ALA administration before laser irradiation of 30J per tumour.
Antitumour effect was more evident in HCC than in the nontumoral tissue surrounding HCC. These findings suggest the possibility to
detect HCC by fluorescence and to treat HCC by light.
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Hepatocellular carcinoma (HCC) is considered to be a highly
therapy-resistant malignancy. Although various kinds of palliative
treatment strategies, such as transcatheter arterial embolisation
(TAE), percutaneous ethanol injection therapy (PEIT) and
percutaneous microwave coagulation therapy (PMCT), have been
employed clinically, the prognosis remains unsatisfactory. New
strategies are required to cure patients with HCC.
Photodynamic therapy (PDT) is a promising local treatment
modality based on the selective accumulation of a photosensitiser
in malignant tissue and the subsequent illumination with laser
light of an appropriate wavelength. In recent years, this therapy
has been successfully used in the management of patients with
various malignant tumours, including cancers of the skin (Fritsch
et al, 1998), gastrointestinal tract (Mimura et al, 1996), lung (Kato
et al, 1989) and uterus (Muroya et al, 1996). Photodynamic therapy
has been considered an unsuitable treatment modality for HCC,
because of the poor tumour-selective accumulation of conven-
tional photosensitiser compared with nontumoral tissue (Gomer
and Dougherty, 1979; Bugelski et al, 1981; Bellnier et al, 1989).
Recently, substantial research has been invested in finding
new tumour localisers with more optimal characteristics for PDT
against HCC.
5-Aminolaevulinic acid (ALA) is a natural precursor to
protoporphyrin IX (PpIX) in the haem biosynthesis pathway of
biological systems. In normal cells, the synthesis of haem and the
precursor PpIX is regulated by a feedback control system. It has
been suggested that this feedback system can be set out of control
if a high amount of ALA is applied to the system exogenously. The
investigators have found that exogenous administration of
ALA can induce the cellular PpIX accumulation (Malik and
Lugaci, 1987; Hua et al, 1995), and this PpIX can be an efficient
photosensitiser (Kennedy and Pottier, 1992). Moreover, it has been
reported that the accumulation of PpIX is greater in malignant
than in normal tissues because of the alteration in the enzyme
profile of the haem biosynthesis pathway (Abels et al, 1994;
Kriegmeir et al, 1996).
Egger et al (1997) indicated that porphyrin accumulation
after ALA administration was greater and continued to increase
for a longer period of time in hepatoma cells than in normal
hepatocytes. Moreover, Svanberg et al (1996) reported that
PDT for transplanted colon cancer to the normal liver was
effective. These results suggest that ALA may be useful for PDT
of HCC. However, the HCC models used in the previous papers
did not reflect the circumstances of human HCC. The present
study is the first to report on PDT in chemically induced
HCC, a model of HCC in situ. Differences between cancerous
and noncancerous tissue and haemodynamics reflect human
liver with HCC better than the previous hepatoma models. To
establish whether PDT might be applicable to HCC, we investi-
gated the possibility of selective accumulation of PpIX and
PDT effect after administration of ALA to the chemically induced
HCC model. Received 4 February 2003; revised 13 May 2003; accepted 22 May 2003
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sMATERIALS AND METHODS
Animals and tumour model
Male Fisher-344 rats (Japan SLC, Hamamatsu, Japan) aged 5 weeks
weighing about 80g were used for hepatocarcinogenesis. They
were housed in animal quarters on a 12-h light–dark illumination
schedule. They had free access to a standard pellet diet (Nippon
Clea Co., Tokyo, Japan) and water. The rats were given distilled
water containing 100ppm of diethylnitrosamine (Tokyo Chemical
Industrial Co., Tokyo, Japan) for 11 weeks to induce HCC, followed
by tap water for 2 weeks. These chemically induced HCC model
rats weighing approximately 200g were used for this study.
In this experimental hepatocarcinogenesis model, the whole
liver weighed 14.8g 73.2 (s.d.). In the liver, various sizes of
tumour from 5 to 15mm in diameter were observed. There were
individual differences in tumour size and number among the
animals. There were different types of hepatocellular lesions in this
chemically induced HCC model at the time of using in this study.
Referring to a report by Williams (1980) and the General Rules for
the Clinical and Pathological Study of Primary Liver Cancer (Liver
Cancer Study Group of Japan, 2000), the liver lesions were
classified pathologically as follows: foci of altered hepatocytes
(FAH, small sublobular lesions of hepatocytes that do not disrupt
the parenchymal architecture), hyperplastic nodules (HN, hepato-
cytic lesions larger than the area of a lobule that disrupt and
compress the surrounding parenchyma but that exhibit minimal to
mild dysplasia), atypical nodules (AN, hepatocytic lesions larger
than the area of a lobule that disrupt and compress the
surrounding parenchyma and that exhibit moderate to severe
dysplasia), HCC (hepatocytic lesions that exhibit advanced cellular
and/or structural atypia consistent with criteria for human HCC).
There was little normal liver tissue in this model. Nontumoral tissue
mainly consisted of FAH and HN, and tumoral tissue mainly
consisted of AN and HCC. This model differs from human HCC in
that it is not associated with cirrhosis. However, the model showed
many hyperplastic nodules resembling cirrhotic pseudolobules and
formation of HCC and precancerous lesions, as in human cirrhosis.
All animal studies were carried out with the approval of our
institutional ethical committee for the care and use of laboratory
animals and met the standards required by the UKCCCR guide-
lines (Workman et al, 1998).
Administration of ALA
Solutions of ALA (Cosmo Bio KK, Tokyo, Japan) were freshly
prepared by dissolving 100mg of ALA in 1ml of phosphate-
buffered saline (PBS: 136.9mM sodium chloride, 2.7mM potassium
chloride, 8.1mM disodium hydrogen phosphate, 1.5mM potassium
dihydrogen phosphate). The pH of the solution was adjusted to
5.0–6.5 using pH indicator paper (Whatman International Ltd,
Maidstone, England) by addition of 1 N sodium hydride. This
solution was used within 10min after preparation. A total of
500mgkg
 1 of ALA was injected through the tail vein under ether
anaesthesia.
The chemically induced HCC model rats were used to measure
the fluorescence intensity at various time intervals after ALA
administration. They were divided into four groups: group 1
(five rats), measured at 1h after ALA administration; group 2
(five rats), measured at 3h after ALA administration; group 3 (four
rats), measured at 6h after ALA administration; group 4 (four
rats), measured without ALA administration.
Fluorescence detection of PpIX in tissue homogenates
The tissue accumulation of ALA-induced porphyrins was deter-
mined by measuring the fluorescence of tissue homogenates at
different times after intravenous administration of ALA. Autopsy
was performed following the animals’ death under deep anaes-
thesia, and the whole liver was removed. Tissue samples, excised
from tumoral and nontumoral tissue of the liver, were frozen at
 801C until fluorescence measurements. The fluorescence mea-
surements of the tumoral parts were performed for all tumours
that were large enough to be measured. In each rat, fluorescence
measurements of the nontumoral tissue were taken from at least
three different sites. Some part of each tissue sample was used for
histopathological study. The rest of the sample, mean 65.8mg, was
homogenised thoroughly in distilled water (100mg wet tissue
6ml
 1 distilled water), and centrifuged at 3000r.p.m. (1000g) for
5min. The supernatants were transferred to a quartz cuvette and
the cuvette was positioned in a spectrofluorometer (FP-777, Japan
Spectroscopic Co. Ltd., Tokyo, Japan). The supernatants were
excited at 410nm, and fluorescence emission was scanned from
550 to 700nm. Background signals were subtracted from the
spectra of the supernatants without ALA. Maximum fluorescence
intensity was detected at 635nm, and this peak was selected for
measurement of the porphyrin content in tissues. The settings of
the fluorometer were adjusted to obtain the optimum signal in the
least amount of time to avoid any possible photobleaching of the
porphyrin.
In the preliminary study, a standard curve was made by the
addition of known levels of PpIX Na to liver tissue extracts from
nontumoral tissue without ALA administration. The standard
curve is shown in Figure 1. It shows a near-linear relationship
between fluorescence intensity measured by FP-777 and PpIX
concentrations.
Fluorescence imaging
Fluorescence imaging in sections of HCC and nontumoral tissue
was achieved using fluorescence photography and microscopy in
order to investigate the difference between HCC and nontumoral
tissues. The whole liver was excised after the animals’ death under
deep anaesthesia at 3h after intravenous administration of
500mgkg
 1 ALA. Fluorescence photography was performed using
a 360nm flash lamp, a colour camera (Bronica ETRSi, Tamron Co.
Ltd., Japan) and lens (Zenzanon PE, Tamron Co. Ltd., Japan)
(Onizawa et al, 1999). To characterise the autofluorescence
elicited, an SC-52 Fuji filter (Fuji Film, Tokyo, Japan), in which
fluorescence below 520nm was absorbed, was set in front of the
lens of the camera. Instant colour film FP-100C (Fuji Film, Tokyo,
Japan) was used in the instant photography camera.
Next, we performed fluorescence micrography using the frozen
sections of 10mm thickness cut by freezing microtome (Cryostats,
Bright Instrument Co. Ltd, England). Tissue sections were
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Figure 1 Standard curve made by the addition of known levels of PpIX
Na to liver extracts from nontumoral parts without ALA administration.
PpIX concentration is expressed as micrograms per liver 100mg.
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sprepared using a ProLong Antifade Kit (Molecular Probes, OR,
USA) and imaged with a minimum of light exposure to avoid
bleaching of porphyrin. A fluorescence microscope (Nikon TE300,
Tokyo, Japan) and  40 objective lens (NA¼0.95) were used.
Using an excitation filter (470715nm) and emission filter (BA
515nm) (Nikon B2A, Tokyo, Japan), the specimen including HCC
and nontumoral tissue was excited with blue light and epifluor-
escence above 520nm was captured with negative film Superia 400
(Fuji Film, Tokyo, Japan).
Photodynamic therapy
PDT was performed on HCC 5–9mm in diameter (four tumours).
ALA at a dose of 500mgkg
 1 was administered intravenously 3h
before laser irradiation. Excimer dye laser (Hamamatsu Photonics
KK, Hamamatsu, Japan) was used to generate light at a wavelength
of 630nm. The output energy was 4mJ per pulse, the repetition
rate was 40Hz, and the power density was 160mW. An 800mm
bare fibre was set to irradiate just above the HCC at a distance of
3–4mm from the tumour surface. The duration of light exposure
was 187s for a total light dose of 30J per tumour (47–90Jcm
 2).
Animals were killed 24h after PDT, and PDT effects were evaluated
histopathologically.
Histopathological study
Some part of the tissue samples fixed in 20% formaldehyde
solution were dehydrated and embedded in paraffin. Sections
(3mm thick) cut from each paraffin-embedded specimen were
deparaffinised and stained with haematoxylin and eosin (HE). All
the sections were examined by the same pathologist and classified
into four tissue types; HCC, AN, HN and FAH, and subsequently
the fluorescence values of all samples were compared. Atypical
nodules were excluded from the present study due to the
insufficient number of measured sites for statistical investigation.
Statistical analysis
For statistical analysis, Student’s t-test was used to obtain a
comparison of the fluorescence intensity between HCC and
nontumoral tissue. The Po0.05 was considered to indicate a
significant difference. The HCC/nontumoral tissue ratio was
expressed as 95% confidence interval (CI).
RESULTS
Fluorescence intensity
Maximum fluorescence intensity of the tissue homogenate was
detected at 635nm both in HCC and in nontumoral tissue after
ALA administration. This peak was selected for measurement of
the PpIX content in tissues because the peak was not detected in
the tissue homogenate without ALA (Figure 2).
Analysis of tissue concentrations of PpIX
Fluorescence intensity of PpIX in HCC and in nontumoral tissue
was compared. The measurements are 16 HCCs and 15 nontumoral
tissues at 1h, 10 HCCs and 19 nontumoral tissues at 3h, eight
HCCs and 13 nontumoral tissues at 6h. Fluorescence intensity in
HCC and nontumoral tissue at various time intervals after
500mgkg
 1 ALA accumulation is shown in Figure 3. The value
was 56.679.7 (mean7s.e.) in HCC, 19.573.6 in nontumoral tissue
at 1h, 279.3767.1 in HCC, 202.0735.3 in nontumoral tissue at 3h
and 166.6737.7 in HCC, 129.9732.3 in nontumoral tissue at 6h.
The fluorescence intensity of PpIX is higher at 3h than at 1h and
6h both in HCC and in the nontumoral tissue. Moreover, at any
time, the fluorescence intensity of PpIX in HCC tends to be higher
than that in nontumoral tissue, and the fluorescence intensity in
HCC is significantly higher (Po0.01) than that in nontumoral
tissues only at 1h.
Figure 3 shows the means of all measured values without taking
individual differences into consideration. However, differences
in PpIX accumulation in different tissue types in the same liver
are important. The HCC/nontumoral tissue ratio was calculated
for each individual liver. The denominator was the mean of
measurements of at least three different sites of nontumoral tissue
in each liver. The HCC/nontumoral tissue fluorescence intensity
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Figure 2 Representative spectra of HCC and nontumoral tissue at
various times after ALA administration. The supernatants of tissue samples
were excited at 410nm, and fluorescence emission was scanned from 550
to 700nm. Maximum fluorescence intensity was detected at 635nm.
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Figure 3 Fluorescence intensity of PpIX in HCC and in nontumoral
tissue at various time intervals after intravenous administration of
500mgkg
 1 ALA. Bars (s.e.) are based on between eight and 19 tissues.
’ HCC, nontumoral tissue. Significant difference: *Po0.01.
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sratio is shown in Figure 4. The mean of this ratio was greater than
1 at every time, which means that the concentration of PpIX in
HCC is higher than in nontumoral tissue. Statistically, selective
accumulation of PpIX in HCC was found at 1 (Po0.001) and 3
(Po0.05) hours after ALA administration.
Fluorescence imaging
A fluorescence photograph of the liver at 3h after 500mgkg
 1
ALA administration is shown in Figure 5. HCC was illuminated by
excitation of blue light. A fluorescence micrograph of the liver at
3h after 500mgkg
 1 ALA administration is shown in Figure 6. The
specimen was illuminated entirely, with the HCC part illuminated
reddish-orange homogeneously due to PpIX.
Photodynamic therapy effect
Based on the above, PDT was performed on HCC at 3h after
500mgkg
 1 ALA administration before 30J per tumour laser
irradiation. In all treated tumours, necrosis was evident at 24h
after ALA-PDT. A representative case with the largest tumour is
shown in Figure 7. In this case, the tumour size was 9mm in
diameter, and therefore the total light dose was 47Jcm
 2. HCC was
completely necrotic; contrastingly, the nontumour tissue sur-
rounding HCC was mostly viable. This indicates that HCC was
selectively damaged after ALA-PDT.
DISCUSSION
Recent advances in diagnostic imaging techniques have increased
the likelihood of detecting HCC. Surgical resection is considered to
be the most curative treatment for HCC. However, surgical
resection is not possible in all patients with HCC, in particular
those who have poor liver function due to underlying cirrhosis.
Furthermore, the cancer frequently recurs even after curative
surgical resection. Therefore, to improve the survival of patients
with HCC, it is imperative to develop a new treatment modality
which is nonsurgical and yet as effective as surgical resection.
Although TAE, PEIT, and PMCT have been widely carried out as
nonsurgical local treatments, the complications and long-term
outcome after these treatments remain unsatisfactory. Recently,
PDT has been successfully used as a local treatment in the
management of patients with various malignant tumours. How-
ever, PDT has not been established for HCC yet. The aim of the
present study was to investigate whether PDT, a therapy with high
tumour selectivity, can be applied to HCC.
In this study, ALA was adopted as a photosensitiser because
there had been some reports on the application of ALA to
hepatoma. Van Hillegersberg et al (1992) have reported selective
accumulation of porphyrin in hepatoma by oral administration of
ALA in rat models in which colon cancer cells had been
transplanted to the liver. In a subcutaneous transplant model of
Morris hepatoma cells to the rat flank, Egger et al (1997) have
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Figure 4 Ratio based on comparison of HCC to the nontumoral tissue
of the same liver. Each dot indicates the ratio of the fluorescence intensity
in the HCC to that in the nontumoral tissue (mean of three to six different
sites). The threshold value at 1 is marked. The mean (bar) of this ratio at
various times is 3.5 at 1h, 1.8 at 3h and 2.2 at 6h after ALA administration.
A 95% CI of the ratio is from 2.3 to 4.7 at 1h, from 1.1 to 2.6 at 3h and
from 0.4 to 4.1 at 6h. Significant difference: *Po0.05, **Po0.001.
Figure 5 (A) Fluorescence photograph of the liver including HCC at 3h
after 500mgkg
 1 ALA administration. The tumour at the edge of the liver
(arrow) was illuminated by excitation of blue light. (B) The specimen
stained with HE. The tumour was revealed to be HCC. Scale: a bar
represents 0.1mm.
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sreported the tumour selective accumulation of porphyrin after
intraperitoneal administration of ALA. Moreover, diethylnitrosa-
mine-treated rats were used as an HCC model for this study
because this experimental model reflects the circumstances of
human HCC better than subcutaneously implanted HCC or
malignant tumour transplanted to the liver. This is the first
demonstration of selective accumulation of PpIX in HCC after ALA
administration and a large antitumour effect after ALA-PDT.
We indicated that PpIX after ALA administration accumulated
predominantly in the HCC as compared with the nontumoral
tissue of the liver in a chemically induced HCC model. First, the
PpIX concentration correlated with fluorescence intensity
(Figure 1) reached a peak value both in HCC and nontumoral
tissues at 3h after administration (Figure 3). This result was
consistent with the report by Egger et al (1997) that PpIX
accumulation reached its highest concentration at 4h after ALA
administration both in the liver and subcutaneously transplanted
HCC. In addition, the fluorescence intensity of PpIX was higher in
HCC than in nontumoral tissue at any time. Moreover, this
difference was significant at 1h after ALA administration (Po0.01)
(Figure 3). This result meant that the ALA uptake was faster in
HCC than in nontumoral tissue and progressively accumulated the
porphyrin in the liver. At 3 and 6h, PpIX concentration in the liver
varied among the individual animals. A possible cause may have
been differences in the amounts of ALA uptake to the liver because
of individual differences in tumour size and number. Another
cause may have been the instability of ALA in the near-neutral
solution. To reduce side effects (Edwards et al, 1984), ALA was
Figure 6 (A) Fluorescence micrograph of the liver including HCC at 3h
after 500mgkg
 1 ALA administration. The right part of the specimen was
illuminated reddish-orange by excitation of blue light. (B) The specimen
stained with HE. Histopathological examination revealed the right part to
be HCC and the left part to be non-HCC. Scale: a bar represents 0.1mm.
Figure 7 Histological sections of the liver including HCC treated with
30J per tumour 3h after 500mgkg
 1 ALA administration. (A) Necrosis
was evident in HCC (T), and the necrotic area was 9mm in diameter and
8mm in depth. Laser irradiation was performed from the topside. The
arrows indicate the necrotic area. (B) Almost all the HCC is occupied with
necrotic tissue. (C) On the contrary, necrosis was not evident in the
nontumoral tissue (FAH) surrounding HCC. Scale: (A) HE, a bar represents
10mm. (B,C) HE, a bar represents 0.1mm.
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sadjusted to pH 5.0–6.5. At pH 7.0, ALA became dimeric to the
extent of 50% after 3h (Elfsson et al, 1998), and the possibility
cannot be denied that the efficacy of ALA rapidly deteriorated as
pH approached neutrality.
Next, we investigated the ratio of PpIX concentration in HCC to
that in nontumoral tissue in each individual because differences in
PpIX accumulation in different tissue types in the same liver were
important when photodynamic diagnosis (PDD) and PDT were
performed. As shown in Figure 4, the mean of the ratio of the
concentration in HCC to that in nontumoral tissue was significant
at 1h (Po0.001) and 3h (Po0.05). At 6h, there were thought to be
individual differences in PpIX metabolism, causing scattered
values. These suggest that PDD and PDT for HCC should be
performed at 3h after ALA administration.
The fluorescence macroscopic findings (Figure 5A) suggested
that the detection of enhanced fluorescence of PpIX in the liver
after ALA administration might be a potential diagnostic imaging
modality for HCC. It may be useful in laparoscopic diagnosis of
tumours near the surface of the liver and intraoperative
investigation of residual tumour at the resected margin. Under
the fluorescence microscope, fluorescence due to PpIX was seen
homogeneously down to the deep portion of HCC, suggesting that
PDT with ALA for HCC may be performed efficiently.
Finally, we demonstrated a large antitumour effect with ALA-PDT.
PDT with an excimer dye laser 3h after photosensitisation caused
necrosis to a depth of 8mm in the same experimental HCC model,
and this necrosis was selective to HCC (Figure 7). The antitumour
effect after ALA-PDT has been considered superficial because in
many previous studies, ALA-PDT was performed after topical
application and necrosis was reported to be shallow (Iinuma et al,
1995; Chang et al, 1996). However, Peng et al (1995) reported
uniform distribution of PpIX throughout clinical noduloulcerative
basal cell carcinoma after systemic administration of ALA, which
was similar to our results (Figure 6A). The large antitumour effect in
our HCC model due to this homogeneous distribution was
comparable to the antitumour effect reported by Regula et al
(1994) by ALA-PDT in cancer transplanted to the pancreas. These
results suggest that optimal outcome in ALA-PDT for nodular
lesions will be obtained by systemic administration.
Another possible reason for the large antitumour effect in this
study is the relatively large dose of ALA compared with previous
reports. Moreover, we cannot rule out the possibility of tissue
specificity to the liver, because haem synthesis, of which ALA is a
precursor, is very pronounced in the liver, and the metabolism
may be even further enhanced in hepatoma, being generated in the
liver. In in vitro experiments using hepatoma cells and normal
liver cells, Kondo et al (1993) have reported high porphobilinogen
deaminase activity and low ferrochelatase activity in hepatoma
cells after ALA administration. Surface illumination, as used in our
study, can produce a selective antitumour effect on large tumours.
However, it is not certain that the laser dose and the manner of
illumination used in this study are optimal. Further study is
necessary to demonstrate the optimal conditions for ALA-PDT on
HCC.
In order to apply ALA-PDT to human HCC, deeper penetration
of the laser beam is required. To achieve this, we believe that
interstitial irradiation is the most effective technique. A similar
technique, PMCT, is being used clinically for the treatment of
hepatoma, showing that technically it is not impossible (Seki et al,
1994). There have also been reports that interstitial irradiation was
effective in treating transplanted hepatoma (Rovers et al, 1998).
We expect that through further research ALA-PDT will become a
safer and more effective treatment modality for HCC.
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